Drug resistant tuberculosis treatment service alignment with health seeking behaviour in selected states in Nigeria

Elias Aniwada
Department of Community Medicine, College of Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.
Search for this author on:
Google Scholar

Ubochioma Emperor

Ubochioma Emperor
National Tuberculosis, Buruli Ulcer and Leprosy Control Program, Federal Ministry of Health, Abuja, Nigeria.
Search for this author on:
Google Scholar

Debby Nongo

Debby Nongo
United States Agency for International Development, Nigeria.
Search for this author on:
Google Scholar

Rupert Eneogu

Rupert Eneogu
United States Agency for International Development, Nigeria.
Search for this author on:
Google Scholar

Omoselewa Oyelaran

Omoselewa Oyelaran
United States Agency for International Development, Nigeria.
Search for this author on:
Google Scholar

Egwuma Efo

Egwuma Efo
KNCV TB Plus, The Hague, Netherlands.
Search for this author on:
Google Scholar

Degu Dare

Degu Dare
KNCV TB Plus, The Hague, Netherlands.
Search for this author on:
Google Scholar

Chukwuma Anyaike

Chukwuma Anyaike
National Tuberculosis, Buruli Ulcer and Leprosy Control Program, Federal Ministry of Health, Abuja, Nigeria.
Search for this author on:
Google Scholar

Article Number - B72748170931
Vol.15(3), pp. 158-165 , July 2023
https://doi.org/10.5897/JPHE2023.1448

Received: 25 April 2023
Accepted: 02 June 2023
Published: 31 July 2023

References

Bieh KL, Weigel R, Smith H (2017). Hospitalized care for MDR-TB in Port Harcourt, Nigeria: A qualitative study. BMC Infectious Diseases 17(1):50. Crossref

Braveman PA. (2003) Monitoring equity in health and healthcare: a conceptual framework. Journal of Health Population Nutrition 21(3):181-192.

Cox HS, Daniels JF, Muller O, Nicol MP, Cox V, van Cutsem G, Moyo S, De Azevedo V, Hughes J (2015) Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa. Open Forum Infect Diseases 2(1):1-7. Crossref

Evans D, Sineke T, Schnippel K, Berhanu R, Govathson C, Black A (2018). Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Services Research. 18(1):973. Crossref

Federal Ministry of Health (FMOH) (2015). National Tuberculosis and Leprosy Control Programme. Annual report, DoP.

Gehre F, Otu J, Kendall L, Forson A, Kwara A, Kudzawu S (2016). The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance. BMC Medicine 14(1):160. Crossref

Gunther G, Gomez GB, Lange C, Rupert S, van Leth F. (2015) Availability, price and affordability of anti-tuberculosis drugs in Europe: A TBNET survey. Eur. Respir. Journal.45:1081-1088. Crossref

Hassan A, Olukolade R, Ogbuji Q, Afolabi S, Okwuonye L, Kusimo O, Osho JA., Osinowo KA,, Ladipo, OA. (2017). Knowledge about tuberculosis: a precursor to effective TB control-findings from a follow-up national KAP study on tuberculosis among Nigerians. Tuberculosis research and treatment. 6309092. Crossref

International Monetary Fund (IMF) (2019) Gross domestic product per capita.

Iruedo J, O'Mahony D, Mabunda S, Wright G, Cawe B (2017). The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province. BMC Infect Diseases 17:1-9. Crossref

Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF (2017). Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study. Clinical infectious diseases 64(11):1502-1508. Crossref

Jokwiro A, Timire C, Harries A, Gwinji P, Mulema A, Takarinda K (2018). Has the utilisation of Xpert® MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test? Public Health Action 8(3):124-129. Crossref

Jombo G, Mbaave PT (2018). Global tuberculosis burden: is Nigeria losing the war? Journal of BioMedical Research and Clinical Practice 1(1):9-11. Crossref

Kruk ME, Freedman LP (2008). Assessing health system performance in developing countries: a review of the literature. Health policy 85(3):263-276. Crossref

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, De Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, Ochoa ER (2015). Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal 45(4):928-952. Crossref

Madhu P (2019). Drug-Resistant TB: A Clear and Present Danger. Forbes.

McLaren ZM, Sharp AR, Zhou J, Wasserman S, Nanoo A (2017). Assessing healthcare quality using routine data: evaluating the performance of the national tuberculosis programme in South Africa. Tropical medicine & international health 22(2):171-179. Crossref

Mnyambwa NP, Lekule I, Ngadaya ES, Kimaro G, Petrucka P, Kim DJ (2018). Assessment of GeneXpert GxAlert platform for multi-drug resistant tuberculosis diagnosis and patients' linkage to care in Tanzania. BMC research notes 11(1):121. Crossref

Mohr E, Daniels J, Muller O, Furin J, Chabalala B, Steele S (2017). Missed opportunities for earlier diagnosis of rifampicin-resistant tuberculosis despite access to Xpert® MTB/RIF. The international journal of tuberculosis and lung disease 21(10):1100-1105. Crossref

Naidoo P, Van Niekerk M, Du Toit E, Beyers N, Leon N (2015) Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests. BMC Health Service Research 15(1):488. Crossref

National Tuberculosis and Leprosy Control Programme (NTBLCP). (2017). "National Tuberculosis Patient Cost Survey," FMOH, Abuja, Nigeria.

NTBLCP/FMOH (2019). Annual TB Report. Nigeria: Federal Ministry of Health.

NTBLCP/FMOH (2020). Annual TB Report. Nigeria: Federal Ministry of Health.

Oga-Omenka C, Bada F, Agbaje A, Dakum P, Menzies D, Zarowsky C (2020). Ease and equity of access to free DR-TB services in Nigeria- a qualitative analysis of policies, structures and processes. International Journal for Equity in Health 19(21):1-13. Crossref

Oliveira O, Ribeiro AI, Krainski ET, Rito T, Duarte R, CorreiaNeves M (2020). Using Bayesian spatial models to map and to identify geographical hotspots of multidrug?resistant tuberculosis in Portugal between 2000 and 2016. Scientific Reports 10:16646. Crossref

Onyedum CC, Alobu I, Ukwaja KN (2017). Prevalence of drug-resistant tuberculosis in Nigeria: a systematic review and meta-analysis. PLoS One 12(7):e0180996. doi: 10.1371 Crossref

The World Bank (2016). Current health expenditure (% of GDP) - Sub-Saharan Africa. View

Timire C, Sandy C, Kumar AM, Ngwenya M, Murwira B, Takarinda KC (2019) Access to second-line drug susceptibility testing results among patients with rifampicin resistant tuberculosis after introduction of the Hain® line probe assay in southern provinces, Zimbabwe. International Journal of Infectious Diseases. 81:236-243. Crossref

Van Den Handel T, Hampton K, Sanne I, Stevens W, Crous R, Van Rie A. (2015). The impact of Xpert® MTB/RIF in sparsely populated rural settings. Int Journal of Tuberculosis and Lung Diseases 19(4):392-398. Crossref

World Health Organization (WHO) (1997). Anti-tuberculosis drug resistance in the world. WHO/TB/97.229. Geneva, Switzerland.

World Health Organization (WHO) (2015). Implementing the End TB Strategy: e Essentials. Geneva.

World Health Organization (WHO) (2018). Engaging private health care providers in TB care and prevention: A landscape analysis. Geneva: World Health Organization.

World Health Organization (WHO) (2019a). Global tuberculosis report.

World Health Organization (WHO) (2019b). No Time to Wait: Securing the future from drug-resistant infections-Report to the Secretary-General of the United Nations.